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1Mitral valve regurgitation (MR) is a rather common finding in heart failure (HF) patients with ischemic or 
nonischemic cardiomyopathy.1,2 MR is a progressive disease 
as it causes chronic left ventricular (LV) volume overload, 
increases right ventricular (RV) pressure, and thereby acceler-
ates the progression of LV dysfunction and HF. There is ample 
evidence about the close relationship existing between MR, 
hospitalization rate, and overall survival.3,4 About 25% to 65% 
of HF patients present MR of variable severity.1,5 In the pres-
ence of ventricular conduction abnormalities, the proportion 
of HF patients with MR substantially increases. Up to 80% to 
85% of patients undergoing cardiac resynchronization therapy 
(CRT) present MR, being of moderate to severe degree in 
≈40% of cases.6–8 Thus, patients with ventricular conduction 
abnormality are at increased risk of worsening HF, hospital-
ization, and death.9 The pathophysiological cascade respon-
sible for higher prevalence of MR in CRT patients has been 
extensively discussed in a recent review by Spartera et al.10 
In addition to well-known anatomic alterations causing MR 
in patients with HF, the presence of spontaneous or pacing-
induced ventricular conduction abnormalities (1) further 
decreases closing forces acting on the mitral leaflets because 
of less efficient myocardial fiber contraction, (2) accentu-
ates tethering forces because of abnormal timing of papillary 
muscles contraction together with the lack of leaflet coapta-
tion, (3) contributes to additional systodiastolic distortion of 
the mitral valve apparatus and its abnormal deformation; and 
finally (4) provokes diastolic MR because of the appearance 
of a diastolic ventriculoatrial gradient as a result of abnormal 
atrioventricular timing. In those HF patients with ischemic 
cardiomyopathy and ventricular conduction abnormalities, the 
presence of scar tissue in proximity or involving a papillary 
muscle adds a structural component to the MR.
See Article by Chatterjee et al
The development of a treatment strategy to reduce MR 
in patients with represents an intense research area includ-
ing catheter-based interventions, surgical minimally invasive 
approaches, and the use of CRT.11–14 Significant decrease in 
MR after CRT has been observed in a substantial proportion 
of patients and attributed to a complex interaction of mecha-
nisms, including recoordination of the papillary muscle clos-
ing forces, reduction in LV volumes with a decrease in mitral 
leaflet tenting angles, and augmentation of transmitral pres-
sure gradient by cause of increased contractility.10 Because of 
amelioration or complete correction of MR by CRT, reduced 
LV filling pressures, decreased postcapillary pulmonary con-
gestion, and reverse cardiac remodeling have been observed.10 
Moreover, relief of HF symptoms, decrease in hospitalization 
rates, and reduction in cardiovascular mortality have been 
consistently reported by several studies conducted in CRT 
patients presenting with MR.10
When treating HF patients with CRT, the big dilemma is 
whether the patient will benefit by this costly therapy (although 
CRT is one of the most cost-effective therapies in HF). Over 
the past 2 decades, numerous invasive and noninvasive pre-
dictors of the response to CRT have been proposed. Among 
the others, a common studied measure of electric delay is the 
QLV interval, ie, the time from the onset of the QRS com-
plex on the surface ECG to the local LV activation at the site 
of the LV lead.15,16 Lead positioning guided by physiological 
parameters (late electric or mechanical activation) rather than 
by anatomic location has shown a greater predictive value for 
a variety of outcome measures.15,17–19 Previous studies demon-
strated the predictive value of QLV interval as a measure of 
LV electric delay for acute hemodynamic changes and clini-
cal outcome with CRT. More recently, Gold et al19 reported 
in a prospectively designed substudy of the SMART-AV trial 
(SmartDelay Determined AV Optimization: A Comparison to 
Other AV Delay Methods Used in CRT) a robust association 
of the RV–LV interval duration with chronic CRT response, 
including ventricular remodeling end points and quality of 
life. RV lead activation time represents a good surrogate of 
the initiation of ventricular activation, particularly when left 
bundle branch block (LBBB) is present. The graded response 
with increasing RV–LV interval duration gives further sup-
port to the value of this measure. Interestingly, this relation-
ship was observed in all major subgroups, indicating that a 
longer RV–LV delay duration predicts a better response than 
parameters associated with traditionally lower CRT response 
rates, such as non-LBBB or QRS duration <150 ms. Gold et 
al19 speculated that the higher nonresponder rates observed in 
the presence of non-LBBB and QRS duration of <150 ms was 
because of a decreased probability of sufficiently long elec-
tric delay at anatomically guided lead positions. In support 
of this hypothesis, patients with non-LBBB and long RV–LV 
interval duration had more than a 2-fold change in left ven-
tricular end-systolic volume compared with LBBB patients 
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with short RV–LV delay duration. Under certain conditions, 
RV–LV delay duration and QLV may be interpreted as equiva-
lent measures of LV electric ventricular delay (albeit not in the 
absolute value) and together demonstrate the ability of simple 
electric measurements to predict improvement in a variety of 
soft end points after CRT.
The physiopathological link between a simple electric 
measurement such as QLV and improvement in MR has been 
recently provided by Upadhyay et al.8 These authors con-
firmed past findings that lower degree of baseline MR and 
greater improvement in MR at 6 months were associated with 
reduced HF hospitalization and mortality after CRT. However, 
this study significantly extended previous knowledge demon-
strating that greater changes in MR were achieved by targeting 
the LV lead in regions of longer QLV at implant.
In this issue, Chatterjee et al20 have analyzed data from 
patients enrolled in the SMART-AV study and provided strong 
evidence of the association between baseline QLV and reduc-
tion in MR after CRT. These authors should be congratulated 
because, by using an extremely robust methodological and 
statistical approach, they contributed to a mechanistic basis 
for the adoption of an electric-targeting LV lead strategy at the 
time of CRT implant. Chatterjee et al20 selected 426 patients 
representing ≈50% of the original SMART-AV study where 
serial echocardiography and interpretable baseline QLV mea-
surements were available. Moreover, final LV lead position 
and echocardiography-based measurements of intraventricu-
lar dyssynchrony, quantified as the time from QRS onset to 
peak systolic velocity adjacent to the annulus at the LV base 
in 6 myocardial segments, were included in the analysis. 
Moreover, dyssynchrony—measured at LV segments adjacent 
to papillary muscles—was additionally assessed. In unad-
justed analysis stratified by median QLV (95 ms), longer QLV 
was associated with less severe MR at 6 months, and larger 
reductions of left atrial volume and filling pressure. Notably in 
the MADIT-CRT study (Multicenter Automatic Defibrillator 
Implantation Trial with Cardiac Resynchronization Therapy), 
CRT patients with LBBB and complete left-sided reverse 
remodeling had significantly lower risks of HF and death, 
solely HF, and solely death during long-term follow-up than 
patients with discordant or lesser reverse remodeling.21 Even 
after multivariable adjustment, QLV remained a significant 
predictor of decrease in MR at 6 months. Interestingly, there 
was a linear relationship between QLV and MR response.
The study by Chatterjee et al20 contains many additional 
clinical important observations.20 The potential mechanism 
of QLV-mediated MR reduction at 6 months was explored 
by evaluating LV resynchronization and LV reverse remod-
eling. A longer QLV (≥ versus < median) was associated 
with greater reduction in LV dyssynchrony and greater LV 
reverse remodeling. In contrast and very surprisingly, 3-month 
changes in mechanical dyssynchrony were not associated with 
the 6-month MR reduction and furthermore did not attenu-
ate the relationship between QLV and 6-month MR reduc-
tion. These data, together with the recent results by Upadhyay 
et al,8 suggest that MR improvement mechanistically appeared 
to be mediated by a reduction in tethering forces achieved 
through favorable LV reverse remodeling, thus contributing to 
better understanding the relationship between QLV and MR 
reduction. Therefore, rather than conducting extensive pre-
implantation assessment searching for the area with the most 
delayed mechanical segment to be targeted at the time of lead 
implantation, selecting an area with long QLV at the time of 
implantation is sufficient to achieve significant MR reduction 
and reverse remodeling.
The lack of correlation between anatomic lead location and 
QLV confirms that the solely anatomy-driven LV lead implan-
tation strategy is suboptimal and it calls for more extensive 
use of multipolar LV lead with possibly independent pacing 
cathodes.22,23 Indeed, in a recent study by van Stipdonk et al,22 
delayed LV lateral wall activation (defined as the area where 
the maximal activation time measured at the LV lateral wall 
was >75% of the total QRS duration) was found in approxi-
mately half of the patients. In these patients, the location of 
the latest activated region was more frequently confined to 
the basal lateral wall, but some individual differences have 
been observed. In contrast, patients without delayed activa-
tion showed more heterogeneous distribution of the latest acti-
vated region on the LV lateral wall. The systematic evaluation 
of LV electric delay by QLV or RV–LV interval duration at 
the time of LV lead implantation seems reasonable. It suggests 
repositioning or using different electrodes (ideally a multi-
polar electrode) with longer electric delays for pacing when 
short intervals are observed. This finding has an increased 
importance in subgroups with lower response rates, such as 
non-LBBB or ischemic cardiomyopathy as recently indicated 
by Gold et al.19 These are groups where the LV activation 
sequence would likely be less predictable because of abnor-
mal LV ventricular activation or scar patterns. It is important 
to note that, although measurements of LV electric ventricular 
delay, such as QLV or RV–LV, are of great help in identify-
ing regions where pacing results in an improved outcome, 
epicardial mapping via the coronary veins is still limited by 
coronary venous anatomy, and some areas cannot be mapped 
because they do not contain any vein. As a result, the ultimate 
proof that pacing at LV electric ventricular delay (whenever 
endocardially or epicardially located) should be achieved by 
any means is still missing.
Although  American Heart Association/American College 
of Cardiology guidelines on valvular heart disease recom-
mend the use of CRT for patients with chronic severe second-
ary MR (stages B to D) who meet the indications for device 
therapy (Level of Evidence A),24 current ESC guidelines on 
valvular heart disease vaguely refer to the use of CRT in HF 
patients and MR.25 However, considering the large body of 
evidence including the present work by Chatterjee et al,20 it is 
reasonable to claim for early adoption of CRT in MR patients 
with abnormal QRS duration and HF. Moreover, as indicated 
by Chatterjee et al,20 the possibility to predict MR improve-
ment by QLV criteria opens the theoretical possibility to cor-
rect MR by pacing at much earlier stage of disease rather than 
considering other established or in-development percutaneous 
interventions. Invasive coronary venous electroanatomic map-
ping eventually integrated with delayed enhancement cardiac 
magnetic resonance could easily be included in the workup of 
patients with MR and HF.26 This subject needs to be addressed 
in a future proof-of-concept study followed by prospective 
randomized controlled trials.
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Does the study by Chatterjee et al20 provide all the 
answers to our questions? Probably not! Long-term results 
are still warranted in a larger cohort and possibly evaluating 
hard end points. Importantly, it is not clear whether there is 
a dynamic change of QLV that may be reflective of reverse 
structural or electric remodeling, thus necessitating continu-
ous assessment of QLV and readjustment of pacing strategy. 
Moreover, this study does not provide sufficient information 
about the outcome of patients with long QLV, in which the 
MR increased or remained unchanged after CRT. By study 
design, patients with persistent or permanent atrial fibril-
lation were not included. It is unclear whether in the pres-
ence of additional important comorbidities, such as severe 
renal failure, a long QLV would be equally predictive of MR 
reduction, improved quality of life, reversal of LV remodel-
ing, reduction of unplanned HF hospitalization, and mortal-
ity. Finally, the role of scar in modulating the outcome has 
not been elucidated; it is possible that in some patients scar 
areas correspond to those presenting long QLV, thus being 
less suitable for pacing. Despite these and other limitations 
already outlined by the authors, the study by Chatterjee et al19 
deserves recognition.
In conclusion, the measurement of LV electric ventricu-
lar delay, such as QLV or RV–LV, is simple, does not require 
echocardiography or surface electrocardiographic measure-
ments, and has the potential to be measured automatically by 
devices that would further simplify lead optimization. The 
possibility that the long QLV could be a marker and possibly a 
target of pacing-correctable MR would open novel treatment 
scenarios to be researched.
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